Payer & Health Plan Administration · Healthcare & Life Sciences
Should you build or buy Out-of-Network Claim Repricing & No Surprises Act Platform?
Out-of-Network Claim Repricing & No Surprises Act Platform software applies benchmark-based pricing to out-of-network claims, calculates Qualifying Payment Amounts under federal NSA rules, manages the Independent Dispute Resolution process, and tracks balance billing compliance. The platform's core value is its access to proprietary market-rate benchmark datasets that make repriced amounts defensible in arbitration.
The build-vs-buy decision for Out-of-Network Claim Repricing & No Surprises Act Platform turns on whether any payer can independently assemble the benchmark datasets that make QPA calculations defensible and whether the NSA's federally mandated methodology leaves any room for differentiation; this has been a stable picture with no meaningful shift.
Build it, buy it, or bridge?
When building makes sense
There is no meaningful build case for OON claim repricing under the No Surprises Act because the value in this category is the benchmark dataset, not the software. QPA calculations must reference market-rate data that vendors like Claritev (formerly MultiPlan) and Zelis assembled over many years and through cross-payer data relationships that no single payer replicates. The repricing algorithm itself follows CMS-mandated methodology, which means the logic is identical across all payers and there's no differentiation to capture from owning it. IDR process management adds another infrastructure layer that requires established arbitrator relationships and process workflows. The only area where internal investment makes sense is in analytics on OON utilization trends and provider billing patterns, which can inform network strategy. That layer sits on top of vendor-managed repricing, not in place of it.
When buying makes sense
Buying is the correct call because the benchmark data required for NSA-compliant QPA calculations is a vendor-controlled asset with no independent substitute. Claritev, Naviguard, Zelis, and Commence Health built their benchmark datasets over years of cross-payer data aggregation, and those datasets are what make a repriced amount defensible when it goes to Independent Dispute Resolution. The repricing methodology itself is federally mandated and applies identically to every payer, which removes any possibility of differentiation from the software. This is compliance infrastructure, similar to EDI clearinghouse connectivity, and vendor selection turns on benchmark network breadth and IDR track record rather than platform sophistication. Savings-percentage pricing means vendor fees scale with what you actually recover, which aligns incentives for the cost containment function this represents.
The desk read
The No Surprises Act gave vendors like Claritev, Zelis, and The Phia Group a structural advantage. The benchmark datasets underlying QPA calculations and IDR process infrastructure are proprietary assets built over years. No single payer independently assembles the market-rate reference data that makes repricing defensible in arbitration. Buying access to that data network is the economic choice, grounded in the practical reality that the data itself took years and cross-payer scale to build.
The NSA repricing methodology is federally mandated and applies identically across payers, which means there's no differentiation to be gained from how you apply QPA. This is compliance infrastructure in the same category as EDI clearinghouse connectivity. The benchmark data is the value, so vendor selection turns on network breadth and IDR track record. Naviguard and Commence Health serve specific parts of the IDR workflow. The build question doesn't have a meaningful answer for the data layer itself.
Frequently asked
What is Out-of-Network Claim Repricing & No Surprises Act Platform software?
Out-of-Network Claim Repricing & No Surprises Act Platform software applies benchmark-based pricing to out-of-network claims, calculates Qualifying Payment Amounts under federal NSA rules, manages the Independent Dispute Resolution process, and tracks balance billing compliance. The platform's core value is its access to proprietary market-rate benchmark datasets that make repriced amounts defensible in arbitration.
When does building Out-of-Network Claim Repricing & No Surprises Act Platform make sense?
There is no practical build path for the repricing and IDR layer because the benchmark data underlying QPA calculations is a vendor-controlled asset that no single payer can independently assemble. Internal investment makes sense only for analytics on top of vendor-managed repricing.
When does buying Out-of-Network Claim Repricing & No Surprises Act Platform make sense?
Buying is necessary for all payers processing OON claims under NSA, because the benchmark data that makes QPA calculations defensible in arbitration is proprietary to vendors and the repricing methodology itself is federally mandated with no room for differentiation.
What are the main Out-of-Network Claim Repricing & No Surprises Act Platform vendors?
Representative vendors include Claritev (formerly MultiPlan), Naviguard (UnitedHealth), Zelis, Commence Health (IDR services). B4 Pro scores the full set.